(Q44473781)

English

Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 December 2017

Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds (English)

1 reference

Europe PubMed Central

3 December 2017

0 references

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum: Comparison of Cognitive Peformances During a Placebo Period and an Atypical Antipsychotic Treatment Period in Schizophrenia: Critical Examination of Confounds

1 reference

10.1038/SJ.NPP.1300349

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1038/SJ.NPP.1300349

Thomas W Weickert

object named as

Thomas W Weickert

1

0 references

Daniel R. Weinberger

6

object named as

Daniel R Weinberger

1 reference

Europe PubMed Central

3 December 2017

author name string

Terry E Goldberg

2

1 reference

Europe PubMed Central

3 December 2017

Stefano Marenco

3

1 reference

Europe PubMed Central

3 December 2017

Llewellyn B Bigelow

4

1 reference

Europe PubMed Central

3 December 2017

Michael F Egan

5

1 reference

Europe PubMed Central

3 December 2017

language of work or name

0 references

publication date

11 June 2003

1 reference

Europe PubMed Central

3 December 2017

Neuropsychopharmacology

1 reference

Europe PubMed Central

3 December 2017

28

1 reference

Europe PubMed Central

3 December 2017

1491-1500

1 reference

Europe PubMed Central

3 December 2017

8

1 reference

Europe PubMed Central

3 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300216

0 references

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Physiological characteristics of capacity constraints in working memory as revealed by functional MRI.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Another view of therapy for cognition in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Psychopathological dimensions in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Clinical profile of an atypical antipsychotic: risperidone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Risperidone versus haloperidol on secondary memory: can newer medications aid learning?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

The effects of head injury in children on neuropsychological and behavioural functioning.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Cognitive recovery after severe head injury. 1. Serial testing on the Wechsler Adult Intelligence Scale

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Relationships among pre- and post-injury intelligence, length of coma and age in individuals with severe closed-head injuries

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Clozapine: new research on efficacy and mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Is it possible to be schizophrenic yet neuropsychologically normal?

2 references

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

7 January 2021

based on heuristic

inferred from DOI database lookup

Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Neuropsychological change in schizophrenia after 6 weeks of clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Dopamine receptors and the dopamine hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

The effect of risperidone on cognition in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Phaeochromocytoma as a cause of reversible dementia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

21 January 2018

EMPLOYMENT CHARACTERISTICS OF DISCHARGED SCHIZOPHRENICS

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

7 January 2021

based on heuristic

inferred from DOI database lookup

WAIS-R short forms in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300216

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.NPP.1300216

1 reference

Europe PubMed Central

3 December 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

3 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44473781&oldid=2025206562"